Metagenomi Therapeutics (MGX) Non-Current Assets (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Non-Current Assets data on file, last reported at $52.4 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $52.4 million, down 18.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $226.7 million (down 20.66% YoY), and the FY2025 annual result was $55.6 million, down 16.62% from the prior year.
• Non-Current Assets retreated to $52.4 million in Q1 2026 per MGX's latest filing, from $55.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $86.6 million in Q4 2023 and troughed at $52.4 million in Q1 2026.
• A 4-year average of $67.9 million and a median of $65.7 million in 2024 frame the typical range for Non-Current Assets.
• On a YoY basis, Non-Current Assets climbed as much as 16.62% in 2025 and fell as far as 23.59% in 2025.
• A 4-year view of Non-Current Assets shows it stood at $86.6 million in 2023, then decreased by 23.02% to $66.6 million in 2024, then retreated by 16.62% to $55.6 million in 2025, then fell by 5.71% to $52.4 million in 2026.
• Business Quant data shows MGX's Non-Current Assets at $52.4 million in Q1 2026, $55.6 million in Q4 2025, and $58.1 million in Q3 2025.